Figure 1: Inhibition of GSK-3β reverses the inhibitory effect of IL-17 on Del-1 expression. | Nature Communications

Figure 1: Inhibition of GSK-3β reverses the inhibitory effect of IL-17 on Del-1 expression.

From: Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway

Figure 1

(a) Del-1 mRNA expression in HUVEC treated for 2 h with the indicated concentrations of IL-17. (b) Similar experimental setup as above for ELISA determination of Del-1 protein levels in culture supernatants after 6 h incubation. (c) HUVEC were stimulated or not with IL-17 (5 ng ml−1; 2 h incubation), in the absence or presence of SB202190 (20 μM; p38 MAPK inhibitor), SP600125 (50 μM; JNK inhibitor), SB216763 (10 μM; GSK-3β inhibitor) or SN50 (50 μM; NF-κB inhibitor). Del-1 mRNA expression was determined by qPCR. Results were normalized to those of GAPDH mRNA and expressed as fold change in transcript levels relative to those of untreated control (medium only), the average value of which was taken as 1. (d) Similar experimental setup as in (c) was used for ELISA determination of Del-1 protein levels in culture supernatants after 6 h incubation. Data are means±s.d. (a,c n=3 and b,d n=5 sets of HUVEC cultures). *P<0.01 compared to control or between indicated groups (ANOVA). NS, not significant.

Back to article page